Sionna Therapeutics (NASDAQ:SION) Director Sells $2,128,201.14 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 47,814 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $44.51, for a total value of $2,128,201.14. Following the transaction, the director owned 3,482,888 shares in the company, valued at approximately $155,023,344.88. This represents a 1.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Trading Up 0.3%

Shares of Sionna Therapeutics stock traded up $0.15 on Thursday, hitting $45.24. 817,609 shares of the company were exchanged, compared to its average volume of 382,339. The company has a 50-day moving average price of $37.40 and a 200 day moving average price of $38.18. Sionna Therapeutics, Inc. has a 1-year low of $9.39 and a 1-year high of $46.10.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.15.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Deutsche Bank AG lifted its stake in Sionna Therapeutics by 4.5% during the fourth quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock worth $413,000 after purchasing an additional 433 shares in the last quarter. Bank of America Corp DE lifted its stake in Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after purchasing an additional 529 shares in the last quarter. MetLife Investment Management LLC lifted its stake in Sionna Therapeutics by 6.6% during the fourth quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock worth $352,000 after purchasing an additional 532 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Sionna Therapeutics by 35.2% during the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock worth $70,000 after purchasing an additional 619 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in Sionna Therapeutics during the fourth quarter worth $36,000.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. UBS Group restated a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Citigroup assumed coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an “outperform” rating on the stock. Raymond James Financial restated a “strong-buy” rating and issued a $53.00 target price on shares of Sionna Therapeutics in a research report on Monday, January 5th. BTIG Research restated a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Finally, Guggenheim lifted their target price on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, Sionna Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $50.57.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.